Bayer AG has raised its combined peak sales forecast for the key growth drivers in the German group's pharmaceuticals portfolio to more than €12bn, and around 40% of that could come from its closely watched antithrombotic asundexian.
Bullish Bayer Highlights Four Future Blockbusters
New Growth Drivers Could Have €12bn Peak Sales
The German group has shone a light at the J.P. Morgan Healthcare Conference on its new launched drugs Nubeqa and Kerendia, plus its late-stage candidates asundexian and elinzanetant, as it prepares for life after patent expiries on Xarelto and Eylea.
More from Strategy
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.